Navigation Links
Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
Date:7/22/2008

e results led to the initiation of a Phase II liver cancer trial that is now open in the U.S., and will shortly begin enrolling patients at sites in South Korea and Canada, as well.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has been used safely in millions of people as part of a worldwide vaccination program against smallpox. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making it dependent on the cellular TK expressed at persistently high levels in cancer cells. To enhance product efficacy, JX-594 is also engineered to express the GM-CSF protein. GM-CSF complements the cancer cell lysis work of the product candidate, leading to a cascade of events resulting in tumor necrosis, tumor vasculature shutdown and an anti-tumoral immune attack.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase II trial for primary liver cancer, demonstrated promising Pha
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
2. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  Sequence, Inc., an industry leader in the field of ... manufacturers is opening a third office location in the "Gateway ... a result of demand by clients to provide cost effective ... allows Sequence to better serve new and existing customers in ... office provides Sequence a hub to support customers ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Global Strategic Business Report" report to their offering. ... Products in US$ Thousands by the following three major Application ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/18/2014)... NAGOYA, Japan , Aug. 19, 2014 ... ASAHI INTECC (Securities Code 7747, Second Section, ... plans to develop a new, differentiated fractional flow reserve ... device intended to improve handling compared to existing FFR ... field in interventional cardiology that exceeds $250 million worldwide ...
Breaking Medicine Technology:Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2Global Anti-Adhesion Products - Strategic Business Report 2014 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4
... results of the Spare the,Nephron (STN) study, ... protocol using CellCept(R) (mycophenolate,mofetil), showed the CellCept-based ... with improved renal function when compared with ... (CNI)., Furthermore, the study showed this ...
... Clinical Phase 2 data presented at American Society of Clinical ... ... MEDX ) today announced updated long-term follow-up and overall,survival (OS) ... ipilimumab in combination with dacarbazine (DTIC) where 11.4%, or 4 of,35 ...
Cached Medicine Technology:Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function 2Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function 3Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function 4Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function 5Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 2Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 3Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma 4
(Date:8/20/2014)... The “Human Insulin Market by ... Premixed), Modern Human Insulin (Rapid Acting, Long Acting, ... Tresiba, Others) - Forecast to 2019” provides a ... current market trends,and strategies impacting the global human ... of the revenue and share analysis. , Browse ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 GBK, the luxury ... 2014 Emmy Award Nominees and Presenters at the annual GBK ... 22nd and 23rd in Beverly Hills from 11am – 6pm. ... and music by DJ Morgan Hildebrand. , As always, GBK ... will feature several charities at the lounge. GO Campaign is ...
(Date:8/20/2014)... VA (PRWEB) August 20, 2014 What ... by Getting Locked Out of the Market, **FDAnews Webinar**, ... EDT, http://www.fdanews.com/DoNowforUDI , Hospitals and other buyers ... due to ineffective product tracking systems. , Complying with ... is customer demands to implement UDI as soon as ...
(Date:8/19/2014)... The elegant bamboo floorings from BambooIndustry.com ... houses in an environmentally conscious way with the company’s ... and have an aluminum oxide finish to help resist ... high-traffic areas. , Recently, the company has released its ... . These fresh items are specially made for global ...
(Date:8/19/2014)... 2014 For decades it has been ... chiropractic adjustments are dangerous and cause strokes, cervical artery ... they do not recommend chiropractic to their patients. Now ... do refer to chiropractors because they have read the ... new research has popped up that tries to cast ...
Breaking Medicine News(10 mins):Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 2Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 3Health News:GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills 4Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 2Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 3Health News:FDAnews Announces — What to Do Now for UDI: Don’t Lose Your Customers by Getting Locked Out of the Market Webinar, Sept. 9, 2014 4Health News:BambooIndustry.com Announces Up To 30% Discount On Its New Click Strand Woven Bamboo Floorings 2Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 2Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 3Health News:Is It True That the Chiropractor Can Cause a Stroke? Dr. Harbison of AlignLife Wood River Speaks Up 4
... Penn Avenue Place buildings participate in World ... Wildlife Fund,s (WWF) Earth Hour, PITTSBURGH, ... Place and Penn Avenue Place facilities,will go dark from 8 to ... companies around the world in the World Wildlife Fund,s,(WWF) Earth Hour ...
... quick laugh and easy smile of a woman who continues ... She still works every day in the family business, heads ... for her energetic grandchildren. , This winter when the ... third time, her oncologist prescribed a new breed of targeted ...
... March 27 The Men,s Health Policy,Center, a ... Network,(MHN), announced today that they are hosting an ... Medicare and Medicaid Services (CMS) practice,that unfairly restricts ... "This petition allows people who are impacted by ...
... New Poll: Teens Still Feel Targeted By Tobacco Advertising ... 27 Kids across D.C. will,rally against tobacco on ... for the 13th annual Kick Butts Day, sponsored by ... across the nation,(for a list of local events, go ...
... The Richard B. and,Lynne V. Cheney Cardiovascular ... have joined the Institute,s Board of Directors. As ... Institute., "Mary Matalin,s experience in public affairs ... Institute as we build our organization and educate,communities ...
... March 27 Clarient, Inc.,(Nasdaq: CLRT ), a ... pharmaceutical industry, today announced,that it is scheduled to make ... Annual Las Vegas Investor Conference at 4:00 p.m. PDT ... is being held at the Palms,Casino Resort April 2-4, ...
Cached Medicine News:Health News:Highmark, Prominent Part of Pittsburgh City Skyline, to Go Dark for One Hour to Support the Environment 2Health News:Saving cancer patients' skin 2Health News:Saving cancer patients' skin 3Health News:Men's Health Policy Center Hosts Petition to Protest Government Barrier to Prostate Cancer Medications 2Health News:D.C. Kids 'Kick Butts' on April 2 2Health News:D.C. Kids 'Kick Butts' on April 2 3Health News:Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors 2Health News:Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2
... The HSV Non-Typing ASR contains primers and ... a 92 bp region of the HSV Type ... requires an instrument that can detect a FAM ... The Cepheid Analyte Specific Reagent* (ASR) program is ...
... compact system is perfect for the office, ... cost effective microhematocrits are required. Featuring a ... offers a range of important benefits: - ... Meets NCCLS standards - Read tubes in ...
... Palomar systems deliver pulsed light over ... multiple power spikes (which may damage skin) ... Cooling technology sends a chilled water supply ... sapphire tip, which is cooled to as ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Medicine Products: